Gallium nitrate (Ganite) has been approved for the treatment of hypercalcemia of malignancy in patients
that do not respond to hydration. Its effectiveness stems from its ability to inhibit bone resorption despite the
presence of tumor-derived factors that promote calcium loss from the bone. Administered by infusion over 24
hours, the typical dose is 200 mg/m2
/day for five consecutive days. A lower dose is recommended if the
symptoms of hypercalcemia are mild (100 mg/m2
/day for 5 days). Steady state is achieved in 24 to 48 hours.
Maintenance of patient hydration is essential during treatment.